Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dr Penelope Ward appointed Glenmark's clinical R&D head

This article was originally published in Scrip

Executive Summary

Glenmark Pharmaceuticals has appointed Dr Penelope Ward as president, clinical R&D, and chief medical officer. Dr Ward, who will be based at Glenmark’s clinical R&D centre in Oxford, UK, will oversee the entire clinical development activity for both new chemical and biological entities. She will also guide all medical activities across Glenmark's branded generic markets. Dr Ward, who has in the past held senior positions in companies such as Pharmacia and Upjohn, GlaxoSmithKline and Roche, was most recently chief medical officer at the Swiss biotechnology company, Novimmune.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts